top of page

Zuranolone for Postpartum Depression

A person in a stylish plaid blazer works on a laptop, seated in a modern and cozy space adorned with abstract art.
A person in a stylish plaid blazer works on a laptop, seated in a modern and cozy space adorned with abstract art.

It’s pretty amazing that this is an option for those experiencing the challenges of postpartum depression. Brexanolone, which was the first medication specifically approved for the treatment of postpartum depression, required administration through a 2-day intravenous infusion. While it marked a significant advancement in the management of this condition, the treatment's format made it largely inaccessible for many birthing partners, particularly those who might not have the time or resources to commit to such an intensive regimen. This limitation underscored the need for more practical solutions in the realm of postpartum mental health care. Zuranolone, on the other hand, represents a groundbreaking alternative that has garnered attention for its accessibility and effectiveness. It is covered by most insurance plans due to the absence of other FDA-approved treatments specifically for postpartum depression. Unlike Brexanolone, Zuranolone is administered as a convenient 14-day course of treatment by mouth, which can be more manageable for individuals navigating the complexities of new parenthood. However, it is important to note that Zuranolone can be quite sedating, which may impact daily functioning. Therefore, I highly encourage birthing partners to arrange for backup childcare during the course of this medication to ensure that they can prioritize their own recovery without added stress. Moreover, one of the significant advantages of Zuranolone is its safety profile regarding breastfeeding. Research indicates that the medication is considered safe for breastfeeding mothers, as only a minimal amount of the drug enters breast

milk. This is a crucial consideration for many new parents who wish to maintain their breastfeeding relationship while also addressing their mental health needs. Overall, the availability of Zuranolone not only provides a new hope for those suffering from postpartum depression but also highlights the ongoing evolution in the treatment landscape for maternal mental health. It is imperative for birthing partners to discuss all available options with their healthcare providers to find the most suitable and effective treatment plan tailored to their individual circumstances.


Comments


Tally Reproductive Psychiatrist, LLC

Private Practice of Jamie Sorenson, MD

3689 Coolidge Court Unit 5

Tallahassee, FL 32311

Call or Text: 850-694-2008

Fax: (786) 590-1485

Email: info@tallyrepropsych.com

Online Scheduling:

https://tallyrepropsych.clientsecure.me/

  • Youtube
  • Instagram
  • Threads
  • TikTok
  • Facebook
  • Linkedin

Telemedicine appointments available only in: Florida, Georgia, Tennessee, Colorado, and Massachusetts

If you are experiencing thoughts of self-harm or are in crisis, please do not use this website. Instead, call or text 988 to reach the Suicide and Crisis Lifeline, or go to your nearest emergency department. If you are outside the United States, please contact your local emergency number.

Conditions Dr. Sorenson has expertise in:

  • Attention Deficit Hyperactivity Disorder (ADHD)

  • Autism Spectrum Disorder (ASD)

  • Obsessive Compulsive Disorder (OCD)

  • Depression or Major Depressive Disorder (MDD)

  • Anxiety or Generalized Anxiety Disorder (GAD)

  • Panic Disorder with and without agorophobia

  • Bipolar Disorder

  • Bipolar 2 Disorder

  • Post Traumatic Stress Disorder (PTSD)

  • Chronic Post Traumatic Stress Disorder (CPTSD)

  • Premenstrual Dysphoric Disorder (PMDD) or Premenstrual Exacerbation of a mood disorder (PME)

  • Perinatal Depression and Postpartum Depression

  • Perinatal Anxiety and Postpartum Anxiety

  • Perinatal OCD and Postpartum OCD

  • Perinatal Psychosis and Postpartum Psychosis

  • Perimenopause/Menopause Mood and Anxiety Disorders

  • Perimenopause/Menopause Cognitive Disorders

  • Gender Dysphoria

  • LGBTQI Mental Health

  • Mood and anxiety disorders while undergoing infertility treatments

Comorbidities not directly treated by Dr. Sorenson that will routinely be considered in your individualized treatment plan and recommendations:

  • Ehlers-Danlos Syndrome

  • Hypermobility Spectrum Disorders

  • Mast Cell Activation Syndrome (MCAS)

  • Postural Orthostatic Tachycardia Syndrome (POTS), dysautonomia, and Mitral Valve Prolapse

  • Fibromyalgia 

  • Chronic Pain

  • Chronic Fatigue Syndrome (CFS)

  • Insomnia and Sleep Apnea

  • Narcolepsy and Idiopathic Hypersomnia

  • Chiari Malformation

  • Small Fiber Neuropathy

  • Pelvic organ prolapse, incontinence, chronic pelvic pain, pelvic floor dysfunction, hernias

  • Irritable Bowel Syndrome (IBS), gastroparesis, gut dysmotility

  • Bladder Pain Syndrome (previously interstitial cystitis)

  • Osteoporosis/Osteopenia

  • Dental Problems/TMJ

  • Migraines and Headaches​

  • Hormone Replacement Therapy (HRT)

  • Infertility Treatment

  • Endometriosis 

  • Polycystic Ovarian Syndrome (PCOS), Now Polyendocrine Metabolic Ovarian Syndrome (PMOS)

  • Thyroid Disorders: Hypothyroidism and Hyperthyroidism

  • Raynaud's Disease

  • Autoimmune disorders: Lupus (SLE), Sjogren's Syndrome, Hashimoto's thyroiditis and Grave's DiseaseCREST SyndromeSclerodermaCeliac Disease and Ulcerative Colitis (UC)Psoriasis/Psoriatic ArthritisRheumatoid Arthritis (RA), Multiple Sclerosis (MS) and Neuromyelitis optica (NMO)

bottom of page